Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) VP Patrick Lamy sold 925 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75. Following the sale, the vice president now owns 17,858 shares of the company's stock, valued at approximately $549,847.82. The trade was a 4.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Akero Therapeutics Stock Performance
AKRO stock opened at $29.03 on Friday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm's fifty day moving average is $30.79 and its 200 day moving average is $27.01. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.15). On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.
Institutional Trading of Akero Therapeutics
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
From Crypto Swap Profits | Ad
All of our key indicators are flashing the same signal: an altcoin season is fast approaching.
And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Register for the FREE Workshop Now & get $10 in Bitcoin
A number of institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Akero Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company's stock worth $71,000 after buying an additional 446 shares during the period. Eastern Bank purchased a new position in shares of Akero Therapeutics in the third quarter valued at about $100,000. Summit Financial Wealth Advisors LLC purchased a new stake in shares of Akero Therapeutics during the third quarter worth about $205,000. Victory Capital Management Inc. purchased a new stake in shares of Akero Therapeutics during the third quarter worth about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Akero Therapeutics during the 3rd quarter valued at about $265,000.
Wall Street Analyst Weigh In
AKRO has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They set a "buy" rating and a $65.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $46.83.
Check Out Our Latest Report on AKRO
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
